U.S. markets closed

Ascendis Pharma A/S (ASND)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
107.97-3.17 (-2.85%)
At close: 04:00PM EST
109.05 +1.08 (+1.00%)
After hours: 06:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close111.14
Bid107.28 x 800
Ask109.75 x 900
Day's Range105.71 - 113.28
52 Week Range105.71 - 178.71
Avg. Volume240,462
Market Cap6.148B
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-8.76
Earnings DateMar 08, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est189.54
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ASND

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ascendis Pharma A/S
    Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Zacks

    Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD

    Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.

  • Benzinga

    Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval

    The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH). The approval for TransCon covers a once-weekly subcutaneous injection for children and adolescents ages 3 to 18 years with growth failure due to growth hormone deficiency (GHD). TransCon hGH is a prodrug of somatropin that provides sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body. The EC a

  • GlobeNewswire

    Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

    TransCon hGH (approved by the European Commission as Lonapegsomatropin Ascendis Pharma) is a once-weekly prodrug of somatropin for pediatric patients diagnosed with growth hormone deficiencyCOPENHAGEN, Denmark, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name TransCon hGH) as a once-weekly subcutaneous injection for the treatmen